Working Meeting in Tomsk

A working meeting took place in Tomsk on October 24-25, 2018, bringing together representatives from the Governor of the Tomsk Region, the Russian Ministry of Industry and Trade, the Siberian State Medical University (SibGMU), the Engineering Chemical-Technological Center of Tomsk State University (IKhTs), and leading enterprises of the pharmaceutical industry. The focus of the meeting was the  «Pharma 2030» Strategy for the Development of the Russian Pharmaceutical Industry. The participants included directors and top managers of 15 enterprises from Moscow, Irbit, Anzhero-Sudzhensk, Kemerovo, Novokuznetsk, and Kurgan.

The program «Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030» was presented by E.V. Denisova, Deputy Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Russian Ministry of Industry and Trade.

«Tomsk has always been a city of science, and we consider it important to hold such conferences to foster dialogue with the industry. One of the directions of the strategy will be subsidizing and assisting startups at critical stages where a promising development might otherwise fail to reach the market»,  - she said.

«The strategies of all Siberian regions set the task of developing biotechnological and biomedical research, but they will not be successful if we do not speak the same language with business»,  - noted L.M. Ogorodova, Deputy Governor of the Tomsk Region for Research and Education.

In her speech, E.V. Tkachenko, General Director of JSC  Avexima, emphasized the importance of the strategic task of providing the industry with qualified personnel, introducing modern technological competencies in the production of medicines and pharmaceutical substances, and fostering cooperative links between production and scientific infrastructure.

 «The implementation of the federal program will elevate the pharmaceutical industry to a new level»,  - she said.

The event program included presentations by participating companies, roundtable discussions on current issues of innovative drug development and their transfer to production, training of specialists for the pharmaceutical industry, and regulatory support for drug registration. Simultaneously, an exhibition of pharmaceutical and medical developments by the meeting participants was held in the House of Scientists.